Oral steroid - predonisolone

ApprovedSmall molecule

IInstituto do Cancer do Estado de São Paulo

Oral steroid - predonisolone is one of 6 small molecule programs targeting Esophageal stricture. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal StrictureActive, not recruiting

Esophageal StrictureApproved

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Esophageal Stricture

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

2 2

Kenalog

Pulmicort

1 4

Decadron

AAspen Global Incorporated

Phase 2

1 5

Oral steroid - predonisolone

IInstituto do Cancer do Estado de São Paulo

Approved

1 6

Tranilast

NNuon Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophageal stricture1 trial

Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture

Unknown status·IInstituto do Cancer do Estado de São Paulo·Phase 4·NCT04498260·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral steroid - predonisolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral steroid - predonisolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral steroid - predonisolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto do Cancer do Estado de São Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IInstituto do Cancer do Estado de São Paulo

Oral steroid - predonisolone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophageal stricture1 trial

References

Drug Info

Quick Facts

Related News